Virus News and Research

Latest Virus News and Research

Rwanda launches Africa's first nationwide cervical cancer vaccination, detection program

Rwandan First Lady Jeannette Kagame on Tuesday, in collaboration with two companies, launched a national cervical cancer vaccination and screening program, the first of its kind in Africa, the New Times reports.

27 Apr 2011

EPO grants patent to Microbix' VIRUSMAX vaccine enhancement technology

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies to enhance vaccine production yields, and other innovative biologics, announced today that the European Patent Office recently granted patent protection for the company's proprietary VIRUSMAX technology, which is designed to increase influenza vaccine yields and has demonstrated an average yield increase of at least two-fold over current vaccine production methods.

27 Apr 2011

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

27 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

New study sheds light on evolution of 2009 pandemic influenza A(H1N1) virus in Japan

Analysis of mutations of the 2009 pandemic influenza A(H1N1) virus by researchers at the RIKEN Omics Science Center (OSC) has revealed major genetic differences between the virus in its early phase of infection in Japan and in its peak phase. While yielding valuable clues on the genetic origins of drug resistance, the findings also pave the way toward the development of new diagnostic kits for detecting and preventing the spread of global pandemic diseases.

26 Apr 2011

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour.

26 Apr 2011

African-American couples with HIV can benefit from health promotion interventions

Interventions to promote healthy behaviors, including eating more fruits and vegetables, increasing physical activity, and participating in cancer screenings, as well as prevention of HIV/sexually transmitted diseases, appear beneficial for African-American couples who are at high risk for chronic diseases, especially if one of the individuals is living with HIV.

26 Apr 2011

Study: More couple-based HIV counseling needed in South Africa

A new study of sexual risk behaviors within long-term couples in South Africa finds that HIV-positive people take almost as much risk in their sexual behavior when they know their partner is HIV-negative or don't know their status, as when they know their partner is already infected.

26 Apr 2011

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

26 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

Study questions suitability of anti-retroviral drugs for the young

According to a new major study one in eight children born with HIV becomes resistant to the three main classes of drugs used to suppress the virus within five years of starting treatment. This is the first major study that looks at drug resistance in 1,000 European children born with HIV. It raises questions about the suitability of anti-retroviral drugs for the young.

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Pharmasset reports net loss of $19.9 million for quarter ended March 31, 2011

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2011.

25 Apr 2011

Avian flu remains endemic in six countries, could take at least a decade to eradicate, FAO says

It will take at least 10 years to eradicate the H5N1 virus from poultry in the six countries where it is endemic, the U.N. Food and Agriculture Organization said in a report released on Thursday, Agence France-Presse reports.

25 Apr 2011

Recent releases in Global Health

When health ministers gather for the World Health Assembly in May they will try to come up with a solution to "a dilemma that has dogged decision-makers for decades - whether and when to destroy the last remaining stocks of the smallpox virus," David Heymann and Emma Ross, both of the Global Health Security Centre at Chatham House, write in an article in The World Today.

25 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Research solves challenging problem of industry-scale production of large RNA molecules

Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.

22 Apr 2011

New study: Children born with HIV are now faring well into adolescence, adulthood

Once facing an almost certain death sentence, most children born with HIV are now faring well into adolescence and adulthood, according to a newly published study co-authored by Tulane infectious diseases expert Dr. Russell Van Dyke. The study was published in the Journal of Acquired Immune Deficiency Syndromes.

22 Apr 2011

The Healthy Home book on reducing health hazards advances in ranking on best sellers lists

The Healthy Home, a new book providing simple solutions for reducing toxins and other health hazards in the home, has advanced in ranking on several national best sellers lists within a month of publication. After becoming a Top 100 Amazon.com best seller following its first week of sales, The Healthy Home, released on March 22, quickly hit the New York Times, USA TODAY, Publishers Weekly and L.A. Times best sellers lists.

22 Apr 2011

Virus News and Research

Latest Virus News and Research

Rwanda launches Africa's first nationwide cervical cancer vaccination, detection program

EPO grants patent to Microbix' VIRUSMAX vaccine enhancement technology

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Researchers develop protein-based inhibitor that can treat HPV

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

New study sheds light on evolution of 2009 pandemic influenza A(H1N1) virus in Japan

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

African-American couples with HIV can benefit from health promotion interventions

Study: More couple-based HIV counseling needed in South Africa

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

Study: HIV infection linked to increased risk of heart failure

Study questions suitability of anti-retroviral drugs for the young

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Pharmasset reports net loss of $19.9 million for quarter ended March 31, 2011

Avian flu remains endemic in six countries, could take at least a decade to eradicate, FAO says

Recent releases in Global Health

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Research solves challenging problem of industry-scale production of large RNA molecules

New study: Children born with HIV are now faring well into adolescence, adulthood

The Healthy Home book on reducing health hazards advances in ranking on best sellers lists

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Virus News and Research

Latest Virus News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in